Basic Information
| LncRNA/CircRNA Name | SNHG7 |
| Synonyms | SNHG7, NCRNA00061 |
| Region | GRCh38_9:136721366-136728184 |
| Ensemble | ENSG00000233016 |
| Refseq | NR_003672 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot etc. |
| Sample | prostate cancer tumor tissue, cell lines (LNCaP, VCaP, 22RV1, DU145, PC-3) |
| Expression Pattern | up-regulated |
| Function Description | SNHG7 expression was significantly up-regulated in prostate cancer tissue and cell lines.Besides, the overexpression of SNHG7 was closely correlated with the poor prognosis. In vitro and in vivo,SNHG7 knockdown markedly inhibited prostate cancer proliferation and cycle-related protein (CDK4, CDK6, Cyclin D1), induced cell cycle arrest at G0/G1 phase and suppressed tumor growth. Moreover, miR-503 was predicted by bioinformatics tools and validated using luciferase reporter assay to both directly inhibited SNHG7 and Cyclin D1 expression by targeting their RNA 3'-UTR. We found that lncRNA SNHG7 acts a ceRNA for miR-503 and harbors miR-503 to positively regulates Cyclin D1 expression. |
| Pubmed ID | 29571017 |
| Year | 2018 |
| Title | Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503. |
External Links
| Links for SNHG7 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |